Purpose: Polyethylenimine (PEI) has been widely used as a versatile template to develop multifunctional nanosystems for disease diagnosis and treatment. In this study, we manufactured iodine-131 ( 131 I)-labeled PEI-entrapped gold nanoparticles (Au PENPs) as a novel nanoprobe for single-photon emission computed tomography/computed tomography (SPECT/CT) imaging and radionuclide therapy. Materials and methods: PEI was PEGylated and sequentially conjugated with Buthus martensii Karsch chlorotoxin (BmK CT, a tumor-specific ligand which can selectively bind to MMP2), 3-(4′-hydroxyphenyl)propionic acid-OSu (HPAO), and fluorescein isothiocyanate to form the multifunctional PEI template for entrapment of Au NPs. Then, the PEI surface was radiolabeled with 131 I via HPAO to produce the novel nanoprobe (BmK CT-Au
Introduction
Nanomedicine holds great promise for diagnosis and treatment of various diseases, particularly cancer. 1, 2 Glioma is the most common intracranial tumor and has the highest mortality rate. 3 Due to the invasive nature of glioma cells, difficulties in accurate delineation of tumor margin and unsatisfactory treatment result in increased mortality. 4, 5 For high grade gliomas, the 5-year survival rate is less than 5%. 6 Thus, it is urgent to develop novel diagnostic and therapeutic options.
Rapid development of nanomedicines has conferred the advantages of different imaging modalities and therapy techniques against this malignant disease. 7 Nuclear medicine is a powerful technology that uses radionuclides for diagnosis and treatment of many diseases. [8] [9] [10] Single-photon emission computed tomography (SPECT), one of the most important radionuclide-based imaging techniques, has shown great value in tumor imaging. [11] [12] [13] [14] Meanwhile, a number of therapeutic radionuclides have been widely used for tumor treatment, including but not limited to iodine-131 ( Ra) . [15] [16] [17] [18] [19] [20] [21] Among these therapeutic radionuclides, 131 I has been routinely used in radionuclide therapy and imaging of thyroid diseases, such as thyroid cancer, because of its high affinity for the thyroid and relatively long half-life (8.01 days). Beta minus decay provides therapeutic effects, while gamma emissions are used for SPECT imaging. 17, 22, 23 Therefore, 131 I-labeled molecular probes have been developed for theranostic applications in treatment of various kinds of cancer. [24] [25] [26] [27] Several studies have suggested that 131 I-labeled gliomatargeting ligands such as chlorotoxin, and chlorotoxin-like peptides such as Buthus martensii Karsch chlorotoxin (BmK CT), are potential candidates for targeted SPECT imaging and radionuclide therapy of glioma. [28] [29] [30] [31] To overcome the main obstacle of blood-brain barrier (BBB), some interventional therapy strategies have been attempted, which have greatly promoted the development of glioma treatment. 32 Computed tomography (CT) is a powerful, noninvasive diagnostic technique that frequently requires additional CT contrast agents for high resolution imaging to allow for more accurate diagnoses. However, commonly-used iodine-based CT contrast agents have short half-lives and poor specificity. 28, 33 Recent studies evaluating gold nanoparticles (Au NPs) have shown that various Au-based CT contrast agents are emerging due to high atomic number, tunable surface chemical modification chemistry, and biocompatibility after appropriate surface modifications. [34] [35] [36] [37] Polyethylenimine (PEI) has the advantages of high-density amines and good water solubility, and it has been widely used as a template to produce multifunctional CT imaging agents. [38] [39] [40] PEI-entrapped Au NPs (Au PENPs) can be easily PEGylated and functionalized with targeting molecules, resulting in prolonged blood circulation time, low toxicity, and designed targeting ability for imaging applications. In addition, PEI has been identified as an excellent vehicle to encapsulate drugs or genes for treatment of different cancers, suggesting that PEI is an excellent template for development of theranostic nanosystems. [41] [42] [43] Our previous work has demonstrated that PEGylated PEI was able to load Au NPs and doxorubicin for tumor-targeted CT imaging and chemotherapy. 44 Furthermore, these Au NPs could be readily labeled with radionuclides for nuclear medicine applications. For instance, we have shown that PEI could be utilized to entrap Au NPs, then labeled with 99m
Tc for SPECT/CT imaging of tumors. 45, 46 However, few studies have evaluated the use of PEI as a vehicle to load therapeutic radionuclides for tumor treatment.
The previous successes and properties of 131 I suggest that PEI may be further utilized as a versatile platform to develop multifunctional nanoprobes for tumor theranostic applications. In this work, we reported the development of 131 I-labeled Au PENPs modified with the glioma-targeting peptide BmK CT for targeted SPECT/CT imaging and radionuclide therapy of glioma. First, PEI was sequentially modified with BmK CT via a PEG linker. Carboxyl-terminated methoxy PEG (mPEG-COOH), 3-(4′-hydroxyphenyl)propionic acid-OSu (HPAO), and fluorescein isothiocyanate (FI) were used to form the multifunctional PEI template. The template was used to entrap Au NPs via sodium borohydride reduction chemistry. Then, the remaining terminal amines were acetylated by acetic oxide (Ac 2 O), and the product was radiolabeled with I labeling were wellcharacterized, including structure, X-ray attenuation coefficient, colloidal stability under different pH and temperature conditions, cytocompatibility at an Au concentration up to 200 μM, and radiochemical stability in vitro. Furthermore, the prepared BmK CT-Au PENPs- 131 I could be utilized for targeted SPECT/CT imaging and radionuclide therapy of glioma cells in vitro and in a xenograft tumor model in vivo. The developed multifunctional Au PENPs may provide a promising theranostic platform for targeted imaging and radionuclide therapy of glioma.
Materials and methods Materials
BmK CT peptide with a cysteine at its I solution (20 mCi, 200 μL). After incubation for 30 minutes at 37°C under continuous stirring, the reaction mixture was eluted through PD-10 desalting columns with PBS as the mobile phase, and 1 mL of liquid was collected in each tube. After ten tubes were collected, the radioactivity of each tube was measured. The radiochemical yield was calculated as (A0-A)/A0. A0 is the total activity of 131 I in the reaction, and
A is the activity of PD-10 desalting column after purification. BmK CT-Au PENPs-
131
I was collected and Au PENPs- 131 I without BmK CT was also prepared for comparison using the same method. Radiochemical purity and radiostability were assessed in vitro according to our previous work.
17
Characterization techniques 1 H NMR spectra of samples dissolved in D 2 O were obtained using a Bruker AV400 nuclear magnetic resonance spectrometer (Bruker AXS Advanced X-ray Solutions GmbH, Karlsruhe, Germany). UV-Vis spectra were collected using a Lambda 25 UV-Vis spectrophotometer (PerkinElmer, Inc., Waltham, MA, USA). Dynamic light scattering (DLS) and zeta potential were measured using a Malvern Zetasizer Nano ZS model ZEN 3600 (Malvern Instruments, Malvern, UK) with a standard 633 nm laser. The Au content of the prepared Au NPs was evaluated using a Leeman Prodigy inductively coupled plasma optical emission spectrometer (Teledyne Leeman Labs, Hudson, NH, USA). Transmission electron microscopy (TEM) samples were prepared by dropping an aqueous particle suspension (1 mg/mL) onto a carbon-coated copper grid, followed by air-drying prior to analysis. TEM imaging was performed using a JEOL 2010F analytical electron microscope (JEOL, Tokyo, Japan) at an operating voltage of 200 kV. The X-ray attenuation properties of the formed Au NPs were compared using Omnipaque (iohexol 300; GE Healthcare, Chicago, IL, USA) at different Au or iodine concentrations (6.25-100 μM). CT images were acquired using a GE Discovery STE PET/CT system (GE Healthcare) with the following settings: 100 kV, 220 mA, and a slice thickness of 1.25 mm. SPECT imaging was performed using a GE Infinia SPECT scanner equipped with an Xeleris workstation and High-Energy GeneralPurpose collimators (GE Healthcare).
Cell culture and construction of glioma-bearing nude mouse model In vitro targeting assay (20, 40, 60, 80 , and 100 μM, respectively). After 4 hours' incubation, the cells were trypsinized, centrifuged, and rinsed with PBS in 1.5 mL microcentrifuge tubes, then imaged using a CT system (GE Inc., USA). After
131
I radiolabeling, the tumor-targeted SPECT imaging capability of BmK CT-Au PENPs- 131 I was evaluated in vitro using a similar method. C6 cells were incubated, then treated with BmK CT-Au PENPs- 131 I or Au PENPs- 131 I at different radioactivity concentrations (0, 25, 50, 100, 200, and 400 µCi/mL). After 4 hours' incubation, the cells were trypsinized, centrifuged, rinsed, and imaged using an Infinia SPECT scanner.
SPECT and CT imaging in vivo
All animal experiments in this study were approved by the ethics committee of Shanghai General Hospital and conformed to the National Institutes of Health Guidelines. Before in vivo imaging, the glioma-bearing nude mice were randomly divided into two groups (five mice per group) and anesthetized with pentobarbital sodium (40 mg/kg). The mice were intravenously injected with PBS solutions containing BmK CT-Au PENPs or Au PENPs ([Au]=100 µM, 100 µL) to evaluate CT imaging performance in vivo. CT images were obtained at 0, 0.5, 2, 4, 6, 8, and 16 hours post-injection. For SPECT imaging, glioma-bearing nude mice were fed and given water containing 1% potassium iodide for 3 days to block thyroid uptake of 131 I. Then, the mice were anesthetized and randomly divided into two groups (five mice per group). We intravenously injected a PBS solution of BmK CT-Au PENPs- 131 I or Au PENPs-131 I at the same dose (500 μCi, 100 μL) into the mice and performed SPECT imaging at 0.5, 2, 4, 6, 8, and 16 hours post-injection using an Infinia SPECT scanner.
In vivo antitumor efficacy
The in vivo therapeutic efficacy of BmK CT-Au PENPs- 131 I was further assessed in a subcutaneous tumor model. To reduce thyroid uptake of 131 I, the tumor-bearing nude mice were fed and given water containing 1% potassium iodide for 3 days. After being divided into five groups randomly (five mice per group), the mice in each group were intravenously injected with 100 μL PBS solutions of BmK CT-Au PENPs-131 I (250 μCi), Au
or Au PENPs (0.1 M Au), or saline. Treatment was administered every 3 days for a total of seven treatments. During treatment, body weight and tumor size were recorded before each injection. After the 21-day treatment period, one mouse from each group was sacrificed to obtain the major organs (heart, liver, spleen, lung, and kidney) and the subcutaneous implanted tumors. The harvested major organs and tumors were stained with H&E according to the standard procedure. To further evaluate apoptosis in the treated glioma-bearing mice, the tumors were stained using the TUNEL method using an apoptosis detection kit (Hoffman'La Roche Ltd., Basel, Switzerland). The stained specimens were imaged using an AMEX 1200 inverted phase contrast microscope.
Statistical analysis
Experimental data in this study were analyzed by one-way ANOVA and the final data were marked with (*) for p<0.05, (**) for p<0.01, and (***) for p<0.001. A p-value <0.05 was considered statistically significant.
Results and discussion
Synthesis and characterization of the BmK CT-Au PENPs- 131 
I
PEGylation has been identified as an effective strategy to improve biocompatibility and pharmacokinetic properties of NPs. In our previous work, PEGylated PEI was successfully used as a template to entrap Au NPs for CT imaging or to encapsulate drugs for chemotherapy of tumors invivo. 41, 44 In this study, PEGylated PEI was sequentially modified with BmK CT peptide using PEG linker, HPAO, and FI, and then utilized to entrap Au NPs. Remaining PEI surface amines were acetylated and the product was radiolabeled with 131 I via HPAO. The Au PENPs modified with BmK CT were used as a multifunctional nanoprobe for tumor-targeted SPECT/CT and radionuclide therapy (Figure 1) Figure S1 ). The average number of mPEG, PEG, HPAO, BmK CT, and FI moieties attached to each PEI was estimated using NMR integration according to our previous work, 11, 29 and the results were recorded in The synthetized Au NPs were analyzed with different techniques. Inductively coupled plasma optical emissionspectrometry was performed to calculate Au content, and the data indicated complete reduction of Au(III) to Au(0) in the BmK CT-Au PENPs and Au PENPs with the average numbers of Au atoms per PEI close to the selected Au salt/ PEI molar ratio. Successful capture of Au NPs within PEI was confirmed by UV-Vis spectroscopy. In agreement with the results reported in the literature, 11 a noticeable surface plasmon resonance peak at approximately 540 nm was clearly observed due to the particle-induced light scattering effect ( Figure S1 ).Furthermore, UV-Vis spectroscopy was used to assess stability of the Au NPs in vitro in the given pH (5.0-8.0) and temperature (4-50°C) ranges. As shown in Figure S2A and B, no obvious changes in absorption characteristics were observed in BmK CT-Au PENPs, indicating acceptable stability under different temperature and pH conditions. BmK CT-Au PENPs' particle size was measured using DLS and TEM. BmK CT-Au PENPs had a hydrodynamic diameter of 147.0±9.1 nm as determined by DLS, and Au core size of BmK CT-Au PENPs was 4.4 ±0.7 nm, as determined by TEM (Figure 2) , smaller than the hydrodynamic size determined using DLS. This was likely due to the fact that TEM only measures the Au core of a single particle, rather than numerous Au NPs in aggregates, as measured by DLS. Notably, the low polydispersity index (0.3±0.06) determined using DLS and the relatively narrow size distribution determined using TEM, suggested favorable size uniformity of the BmK CT-Au PENPs. TEM also showed that BmK CT-Au PENPs were nearly spherical in shape, and high resolution TEM images further showed Au crystal lattices, suggesting high crystallinity of the formed BmK CT-Au PENPs ( Figure 2C ). This was confirmed through evaluation of selected area electron diffraction patterns, where the featured (111), (200), (220), and (311) rings were used to confirm the face-centered-cubic crystal structure ( Figure 2D ). Energy dispersive spectroscopy of BmK CT-Au PENPs samples indicates the existence and distribution of Au elements ( Figure 2E ). Finally, surface potentials of the BmK CT-Au PENPs and Au PENPs were estimated at 6.06±0.16 mV and 14.5±0.15 mV, respectively, demonstrating successful acetylation of the remaining surface amine groups of PEI. The prepared Au NPs were readily labeled with 131 I using the chloramine-T method due to the presence of HPAO on the surface of PEI. The radiolabeling yields of BmK CT-Au PENPs- 131 I and Au PENPs-131 I were 77.0 ±4.97% and 72.3±3.62% (n=3), respectively. After purification using a PD-10 column, the radiochemical purities were greater than 99%, and they remained above 90% after exposure to PBS at room temperature and FBS at 37ºC for 24 hours ( Figure S2C and D) , indicating excellent radiostability, which allowed for further in vitro and in vivo analyses.
Cytotoxicity assay
CCK-8 assay was used to assess the potential cytotoxicity of BmK CT-functionalized Au PENPs before and after 131 Targeting specificity of the BmK CT-Au PENPs to tumor cells
BmK CT is a tumor-specific ligand and can selectively bind to MMP2 which is overexpressed in various tumors. Based on this property, BmK CT-Au PENPs were expected to specifically target C6 cells. Flow cytometry ( Figure S4 ) and confocal microscopy ( Figure S5 ) were used to assess targeting specificity of BmK CT-Au PENPs. Flow cytometry assay showed that the fluorescence intensity in C6 cells treated with BmK CT-Au PENPs for 4 hours was significantly higher than that in cells treated with untargeted Au PENPs at the same concentration (p<0.05). In contrast, the fluorescence intensity in C6 cells treated with Au PENPs was similar to that in the PBS control. These results demonstrated that the targeted ligand BmK CT increased uptake of Au PENPs into C6 cells. Similarly, enhanced cellular uptake of BmK CT-Au PENPs was visualized using confocal microscopy. After treatment with BmK CT-Au PENPs for 4 hours, C6 cells displayed prominent fluorescence signals, while cells treated with Au PENPs at the same concentration exhibited similar fluorescence signals to those of the PBS control, further confirming that uptake of BmK CT-Au PENPs in C6 cells was enhanced by modification with BmK CT. Thus, the synthetized BmK CT-Au PENPs displayed high targeting specificity to C6 cells based on flow cytometry and confocal microscopy analyses.
SPECT and CT imaging in vitro
SPECT and CT performance of BmK CT-Au PENPs were first evaluated in vitro (Figure 3 ). Due to high X-ray attenuation, Au NPs have been explored as contrast agents for CT imaging. In this study, the formed BmK CT-Au PENPs were compared with Omnipaque (a small molecule CT contrast agent used clinically) to investigate the effects of high X-ray attenuation on performance. As shown in Figure 3A -C, both Au NPs and Omnipaque had brighter CT images and higher HU values as their concentrations increased, while a sharper trend of Au NPs could be clearly seen as a result of larger HU values than Omnipaque at the same Au or I concentrations, revealing stronger X-ray attenuation by Au NPs than by iodinebased contrast agents. Similarly, for CT imaging in vitro, the brightness of CT images increased with increasing Au concentrations in the cells treated with BmK CT-Au PENPs and Au PENPs ( Figure 3D and E). Quantitative analysis showed that a higher CT value was obtained in the C6 cells treated with BmK CT-Au PENPs than those treated with Au PENPs at Au concentrations of 20, 40, 60, 80, and 100 μM ( Figure 3F) . At an Au concentration of 100 μM, cells treated with BmK CT-Au PENPs showed a 2.2 times higher CT value than those treated with Au PENPs, indicating that BmK CT modification enhanced cellular uptake of Au PENPs into C6 cells. SPECT images of C6 cells treated with BmK CTAu PENPs-131 I were clearly brighter than those treated with Au PENPs-131 I at the same radioactivity concentrations ( Figure 3G and H). Further quantitative analysis demonstrated that the radioactive signal intensity in the BmK CT-Au PENPs-131 I group was significantly higher than that in the Au PENPs-131 I group, especially at the radioactivity concentration of 400 µCi/mL ( Figure 3I ). These data indicated that BmK CT-Au PENPs-131 I allowed for excellent SPECT imaging of gliomas in vitro. In addition, biodistribution analysis was also performed to assess differences in tumor SPECT signal intensity between the BmK CT-Au PENPs-131 I and Au PENPs-131 I groups at 8 hours post-injection. As shown in Figure S6 , 131 I-labeled Au NPs were mainly absorbed by the liver, stomach, and intestines, with relatively low radioactivity in other organs. In contrast, much higher tumor uptake of BmK CT-Au PENPs-131 I was observed compared with that of Au PENPs-131 I, further demonstrating BmK CT-dependent enhancement of tumor uptake. Due to the targeting ability of BmK CT, similar results were observed in CT imaging of BmK CT-Au PENPs in tumor-bearing nude mice. As shown in the Figure 5A and B, the anatomic structure of implanted tumors in mice could be seen in the CT images of both the BmK CT-Au PENPs and Au PENPs groups before injection. Peak tumor CT values were observed at 8 hours post-injection, followed by a gradual decrease in mice treated with BmK CT-Au PENPs and Au PENPs. Quantitative results showed higher CT tumor values in the BmK CT-Au PENPs group during the study period ( Figure 5C ). In particular, the HU value of tumors in the mice treated with the BmK CT-Au PENPs was 1.67 times higher than that in mice treated with the Au PENPs at 8 hours post-injection. According to SPECT and CT data, prepared BmK CTAu PENPs possessed targeting specificity to gliomas in vivo and could be used as a nanoprobe for SPECT/ CT imaging. International Journal of Nanomedicine
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